JP2020502281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502281A5 JP2020502281A5 JP2019554495A JP2019554495A JP2020502281A5 JP 2020502281 A5 JP2020502281 A5 JP 2020502281A5 JP 2019554495 A JP2019554495 A JP 2019554495A JP 2019554495 A JP2019554495 A JP 2019554495A JP 2020502281 A5 JP2020502281 A5 JP 2020502281A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bacteria
- composition according
- parabacteroides
- akkermansia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 96
- 241000894006 Bacteria Species 0.000 claims description 80
- 241000160321 Parabacteroides Species 0.000 claims description 41
- 241000702460 Akkermansia Species 0.000 claims description 39
- 235000013305 food Nutrition 0.000 claims description 11
- 206010010904 Convulsion Diseases 0.000 claims description 9
- 241000204306 Parabacteroides merdae Species 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 3
- 241000702462 Akkermansia muciniphila Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 206010053398 Clonic convulsion Diseases 0.000 claims 1
- 208000034308 Grand mal convulsion Diseases 0.000 claims 1
- 206010043994 Tonic convulsion Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 72
- 235000020805 dietary restrictions Nutrition 0.000 description 27
- 235000020887 ketogenic diet Nutrition 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 description 6
- 230000009529 traumatic brain injury Effects 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 4
- 208000012268 mitochondrial disease Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 208000001914 Fragile X syndrome Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000006289 Rett Syndrome Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 208000029560 autism spectrum disease Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000001123 neurodevelopmental effect Effects 0.000 description 2
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- -1 gamma-glutamyl amino acid Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 230000002361 ketogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436711P | 2016-12-20 | 2016-12-20 | |
| US62/436,711 | 2016-12-20 | ||
| US201762447992P | 2017-01-19 | 2017-01-19 | |
| US62/447,992 | 2017-01-19 | ||
| PCT/US2017/067548 WO2018119048A1 (en) | 2016-12-20 | 2017-12-20 | Compositions and methods for inhibiting seizures |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502281A JP2020502281A (ja) | 2020-01-23 |
| JP2020502281A5 true JP2020502281A5 (enExample) | 2021-02-04 |
| JP7166280B2 JP7166280B2 (ja) | 2022-11-07 |
Family
ID=62627881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554495A Active JP7166280B2 (ja) | 2016-12-20 | 2017-12-20 | 発作を抑制する組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11129858B2 (enExample) |
| EP (1) | EP3558329B1 (enExample) |
| JP (1) | JP7166280B2 (enExample) |
| CN (2) | CN119033822A (enExample) |
| AU (1) | AU2017382197B2 (enExample) |
| CA (1) | CA3047397A1 (enExample) |
| WO (1) | WO2018119048A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119033822A (zh) | 2016-12-20 | 2024-11-29 | 加利福尼亚大学董事会 | 用于抑制癫痫发作的组合物和方法 |
| JP6840272B2 (ja) * | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| JP7520820B2 (ja) * | 2018-09-20 | 2024-07-23 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 筋萎縮性側索硬化症の治療方法 |
| CN113164527A (zh) * | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| KR102340392B1 (ko) * | 2018-10-08 | 2021-12-17 | 한국생명공학연구원 | 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도 |
| CN110227085A (zh) * | 2019-07-16 | 2019-09-13 | 江苏省中医院 | Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用 |
| CN115916227A (zh) * | 2020-06-12 | 2023-04-04 | 森永乳业株式会社 | 线粒体功能改善用组合物 |
| CN113367328B (zh) * | 2021-06-11 | 2023-02-21 | 无锡市人民医院 | 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方 |
| EP4373502A1 (en) * | 2021-07-20 | 2024-05-29 | Université catholique de Louvain | Prevention and/or treatment of reward dysregulation disorders |
| WO2023001368A1 (en) * | 2021-07-20 | 2023-01-26 | Université Catholique de Louvain | Prevention and/or treatment of reward dysregulation disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| WO2014075745A1 (en) * | 2012-11-19 | 2014-05-22 | Université Catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CA2940226A1 (en) * | 2013-02-22 | 2014-08-28 | The Regents Of The University Of California | Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life |
| KR101445243B1 (ko) * | 2014-03-28 | 2014-09-29 | 서울대학교산학협력단 | 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| KR20180010237A (ko) * | 2015-05-21 | 2018-01-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 건강 증진을 위한 박테리아 집단 |
| PT3297644T (pt) | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| CN119033822A (zh) | 2016-12-20 | 2024-11-29 | 加利福尼亚大学董事会 | 用于抑制癫痫发作的组合物和方法 |
| US20220184084A1 (en) | 2019-03-18 | 2022-06-16 | The Regents Of The University Of California | Compositions and methods for treating cushing's disease |
-
2017
- 2017-12-20 CN CN202411196564.7A patent/CN119033822A/zh active Pending
- 2017-12-20 JP JP2019554495A patent/JP7166280B2/ja active Active
- 2017-12-20 CN CN201780086503.7A patent/CN110325196B/zh active Active
- 2017-12-20 CA CA3047397A patent/CA3047397A1/en active Pending
- 2017-12-20 EP EP17882543.6A patent/EP3558329B1/en active Active
- 2017-12-20 WO PCT/US2017/067548 patent/WO2018119048A1/en not_active Ceased
- 2017-12-20 US US16/471,460 patent/US11129858B2/en active Active
- 2017-12-20 AU AU2017382197A patent/AU2017382197B2/en active Active
-
2021
- 2021-09-27 US US17/486,299 patent/US11883441B2/en active Active
-
2023
- 2023-12-20 US US18/390,652 patent/US12364717B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502281A5 (enExample) | ||
| AU2023201538B2 (en) | Methods and compositions using Bifidobacterium longum to treat or prevent depressive symptoms | |
| CN108541221B (zh) | Hmo的混合物 | |
| Kaźmierczyk-Winciorek et al. | The immunomodulating role of probiotics in the prevention and treatment of oral diseases | |
| JP7523493B2 (ja) | 情動的反応を制御するため、並びに潜在的な気分変調の治療及び予防のための、ビフィドバクテリウム・ロンガムを用いる、方法及び組成物 | |
| US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
| US11959067B2 (en) | Bifidobacterium lactis strain for preventing or treating colitis and method for preventing or alleviating colitis | |
| JP2012512171A (ja) | 改善された口腔健康のための組成物及び方法 | |
| ES2763350B2 (es) | Cepa de christensenella minuta y uso de la misma | |
| CN113355255A (zh) | 罗伊氏乳杆菌lm1071菌株及包含其培养物的组合物 | |
| US10111915B1 (en) | Method to treat fatty liver disease using Parabacteroides goldsteinii | |
| RU2441652C2 (ru) | Лечение общих расстройств развития | |
| JP2020520928A (ja) | 細菌株を含む組成物 | |
| US20130022577A1 (en) | Probiotic compositions useful for treatment of bipolar disorder | |
| CN111556755A (zh) | 用于治疗偏头痛的人乳寡糖 | |
| Loo et al. | A Current Overview of Next-Generation Probiotics and Their Prospects in Health and Disease Management | |
| Nagaraj et al. | Probiotics and oral health | |
| Georgieva et al. | Probiotics: past, present, and future challenges | |
| JP6671950B2 (ja) | 機能性胃腸症改善剤 | |
| WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
| CN115381924B (zh) | 一种用于神经修复的组合物及其制备方法 | |
| Sayar et al. | Psychobiotics: the potential therapeutic promise of microbes in psychiatry | |
| CN116019837A (zh) | 约氏副拟杆菌dsm18315在预防或治疗肥胖或其相关疾病中的应用 | |
| US20200375204A1 (en) | Bifidobacterium longum ncimb 41676 | |
| WO2005072718A1 (ja) | 乳清発酵物を含有する医薬組成物 |